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Abstract Article Info 
Introduction: Nasopharyngeal carcinoma (NPC) frequently occurs in Indonesia which is endemic to several 
countries of Asia, specifically in southeastern China, and is associated of infection with Epstein-bar virus (EBV). 
In recovery, radiation therapy plays a vital role. Chemotherapy will increase the local control rate/disease control 
rate (DCR) in cases with an advanced local stage. 
Case report: A 49-year-old man felt a lump in his neck accompanied by ringing in his ears and sore throat. 
Physical examination showed a tumor in the right nasopharynx enlarged into the parapharynx cavity and closed 
Rosenmuller's fossa. The results of the biopsy were positive for non-keratinized, undifferentiated (WHO-3) type 
A nasopharyngeal carcinoma (NPC), moderate malignancy. The planned treatment consists of a combination of 
chemotherapy and radiotherapy. Chemotherapy is given 3 cycles before radiotherapy (neo adjuvant) and 3 
cycles of concurrent radiotherapy (adjuvant). The total dose of radiotherapy given was 6,600 c Gy and supra 
clavicle 5,400 c Gy with fractionation of 33 times in the tumor and 27 times in the supra clavicle.   
Conclusion: The results presented 6 months after radiotherapy were complete response to loco regional tumors 
with well tolerated side effects.  
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1. CASE REPORT 
Nasopharyngeal carcinoma (NPC) is a type of cancer that often occurs in 
Indonesia and is endemic in several regions in Asia, especially in southeast 
China, and is associated with the presence of Ebstein barr Virus (EBV) infection 
[1]. Radiotherapy plays an important role in treatment. In cases with an advanced 
local stage, chemo therapy can increase the local control rate / disease control 
rate (DCR) [1, 2].  
Conformal 3D radiotherapy is used to improve the conformity of dose 
distribution in tumors whose lesions are shaped like a horseshoe encircling the 
organ at risk and reduce the dose in the organs at risk, namely in the brain stem, 
optic nerves and chiasm, temporal lobe, parotid gland and others [1]. The 
standard of treatment for advanced NPC is a combination of radiotherapy and 
chemotherapy. Several randomized studies and meta-analyzes reported that NPC 
treatment with neo-adjuvant chemotherapy followed by radiotherapy and 
followed by adjuvant chemotherapy with good results [1]. 
The radiotherapy target volume consists of the initial target volume and the 
volume booster; the initial target volume for stage IV NPC was adjusted 
accordingly include the extension of clivus disease, fossa cranial, infra temporal 
fossa, or hypopharynx. It should be noted that when entering radiotherapy 
coverage to the basal brain and intra cranial, it should not exceed the normal 
tissue tolerance dose limit value. For a volume booster is given in the area that 
exceeds the 0.5 to 1 cm mark from the gross tumor depending on the type of 
normal area around the tumor, for examplefor tumory that has an extension of 
clivus to avoiding radiotherapy to the brain stem so it can only be given a few 
millimeters considering the critical tolerance dose is> 60 Gy. The dose of 
radiotherapy with 3D conformal technique is 66 to 70 Gy on CTV, given in 33 
fractions [1]. In Indonesia, the cannasopharynx (upper part of the pharynx or 
throat) is the number 4 malignant cancer after uterine, breast and skin cancer. 
This cancer most often occurs in the ENT, head and neck. The spread of this 
cancer can develop to the eyes, ears, neck glands, and brain [3] 
NPC is included in the top five malignant tumors with the highest frequency, 
while the head and neck area occupies the first place. NPC is derived from the 
rosenmuller fossa in the nasopharynx which is a transitional area where the 
cuboidal epithelium turns into a squamous epithelium. The radiation-sensitive 
nature of tumors makes concurrent chemoradiation the mainstay of treatment for 
advanced local NPC cases. However, NPC still has quite a lot of local recurrences 
and distant metastases [4, 5]. 
NPC is radioresponsive so radiotherapy remains the most important therapy. 
Radiation in tissues can cause ionization of water and electrolytes from both intra 
and extra cellular body fluids, resulting in highly reactive H + and OH- ions 
which cause degeneration or cell death [6]. The ion can react with DNA mole 
cules in the chromosome, so that DNA double chains can break out, changes in 
cross-linkage in the DNA chain and changes in base. Radiotherapy has both local 
and systemic side effects. Despite its side effects, radiotherapy remains the   
treatment of choice in NPC because it is  very  radiosensitive  and  the  difficulty  
of curative therapy is surgery due to the location of the nasopharynx at the base 
of the skull [6]. The lethal dose and the ability to repair damage to cancer cells 
are lower than normal cells, so that due to radiation more cancer cells die and 
remain damaged than normal cells. The surviving cells will carry out the DNA 
damage repair by themselves. Normal DNA cell repair ability is better and faster 
than cancer cells [7]. This condition is used as the basis for radiotherapy to the 
cancer. Radiotherapy at NPC can cause side effects, namely local and systemic. 
In determining disease-specific survival, deaths as a result ofuncontrolled disease 
or treatment-related complications wereboth counted as events, whereas deaths 
as a result of intercurrentdisease were regarded as censored observations [8]. 
In the case report: radiotherapy with neoadjuvant chemotherapy on 
nasopharyngeal carcinoma (NPC) advanced stage using the 3D Conformal 
Radiotherapy (3D CRT) Method. 3D CRT is a treatment in which planning 
and delivery treatment is based on 3-D volumetric imaging with each radiation 
field according to the target volume form "conformity" [9].  
Radiotherapy treatment for nasopharyngeal carcinoma through several 
processes or stages. Consultation and diagnosis first, before starting radiation 
therapy, the patient will go through the CT Simulator stages. At this point, the 
radiation oncologist will determine the location of the body that will receive 
the radiation. Then, the best position determination will be selected based on 
irradiation techniques and objectives that can be reproductively applied to each 
radiation fraction. Markers or markers are intended as reference points to assist 
in positioning the patient when irradiated. These markers or markers must not 
be lost or erased and the radiotherapy team must care about the patient how to 
retain the markers [10]. 
In a simulator process with a CT scan, the patient is positioned in a supine 
position, with the fixation of a thermoplastic mask for immobilization of the 
head and neck, including the shoulders. Administration of intravenous contrast 







is very helpful in delineating GTV, especially in the lymph nodes. Fusion with 
other imaging modalities such as MRI can be performed preferably with a slice 
thickness of at least 3 mm. The skull base (intracranial clivus and nerves) is 
excellent when viewed on MRI. Marrow infiltration is best seen in non-
contrast T1 MRI sequences [11]. 
In patients with 3D CRT technique with nasopharyngeal cancer cases, it 
is better to use a 4 point thermoplastic mask, because it is to better fix the head, 
neck and shoulder areas so that the position is fixed and does not change. For 
the 3 point thermoplastic mask, it does not fix the shoulder, so the position of 
the shoulder can change [12]. 
The definition of CRT 3D radiation targets must be based on the 
terminology of the International Commission on Radiation Units and 
Measurements-50 (ICRU-50), namely gross tumor volume (GTV), clinical 
target volume (CTV) and planning target volume (PTV). In the CT-scan 
simulator process, the patient is positioned in a supine position, with the 
fixation of a thermoplastic mask for immobilization of the head and neck, 
including the shoulders. [13]. 
The purpose of writing a case report: radiotherapy with neoadjuvant 
chemotherapy on nasopharyngeal carcinoma (NPC) advanced stage is to 
report the results of radiotherapy in advanced nasopharyngeal carcinoma 
assisted by neo adjuvant chemotherapy. 
A 49 year old man presented with enlarged right side of the neck and 
complained of ringing in the ears, sore throat and dry mouth. The results of the 
CT scan on 15-11-2018 showed several enlargement of the lymph nodes clear 
in the neck, especially on the right, the largest one on the right is 49.7x32.09 
mm in diameter, while the one on the left is 38.39x24.39 mm in diameter. 
In the sagittal section of the right-sided region, several lymph nodes were 
seen, all of which were 9.17 x 6.26 cm in diameter and the mass in the right 
nasopharynx (Picture 1) had filled the right parapharynx and entered the right 
tubarian torus, Rosenmuller's fossa back wall; The clivus, sella wall and right 
temporal middle fossa were still intact, the para-nasal sinuses, especially the 
sphenoid and bilateral maxillary sinuses were still clean (T2N3M0) (Pictures 
2, 3 & 4). 
The biopsy was positive for non-keratinized, undifferentiated (WHO-3) 
type A NPC, moderate malignancy. The planned treatment consists of a 
combination of chemotherapy and radiotherapy. Chemotherapy is given 3 




Picture 1. CT Scan Before Radiotherapy and Neo Adjuvant Chemotherapy 
Axial Section of the Right Nasopharynx 15-11-2018 
 
Picture 2. CT Scan Before Radiotherapy and Neo Adjuvant Chemotherapy 
Coronal Cross Section at 15-11-2018 
 
Picture 3. CT Scan before Radiotherapy and Neo Adjuvant Chemotherapy 
Right Sagittal Cross Section at Several Lymph Nodes 15-11-2018 
 
Picture 4. CT Scan Before Radiotherapy and Neo Adjuvant Chemotherapy 
Axial at Lymph Nodes 15-11-2018 
 
The patient after undergoing three cycles of neo adjuvant chemotherapy 
on 20-02-2019 and CT scan on 26-03-2019 saw a smaller tumor mass in the 
enlarged right neck. From the size that can be seen in the sagittal section, it is 
9.17 x 6.26 cm (Picture 3) to 6.61 x 5.21cm (Picture 5). 
 







Picture 5. CT Scan When Simulator After Neo Adjuvant Chemotherapy 
Axial, Sagittal and Coronal Cross Sections 26-03-2019 
Radiotherapy simulation techniques and radiation field planning were 
performed by initially setting the patient lying on his back and immobilized 
with a head and neck thermoplastic, then performing a CT scan of the head and 
neck simulator (Pictures 5). 
The next step is to make a contour of the tumor mass with its spread and 
enlargement of the lymph nodes, and the surrounding organs at risk. Contour 
results were sent to the treatment planning system (TPS) to calculate the dose 
volume histogram (Pictures 6 & 7). 
Picture 6. Isodosis Curve (Dose Volume Histogram) 
Radiation planning was calculated using TPS, the next step was to perform 
radiotherapy with a total dose of 66 Gy in the head, neck and supraclav in 33 
fractionations (2 Gy / day). The total dose was obtained on GTV 95 = 99%, 
CTV 95 = 98% and PTV 95 = 95% while CTV supraclav 95 = 99% and PTV 
supraclav 95 = 96%. The dose in the organ at risk is brain steam 39.84 Gy 
(dmax = 54 Gy), esophagus 3.92 Gy (dmax = 34 Gy), spinal cord 40.77 Gy 
(dmax = 45 Gy), the dose in the small chiasma is 1.46 Gy (dmax = 54 Gy) 
because the tumor extends more to the inferior, right eye lens 0.3 Gy (dmax = 
0.45 Gy), left eye lens 0.31 Gy (dmax = 0.45 Gy), right ocular bulb 0.39 Gy 
(dmax = 0.8) and left ocular bulb 0.45 Gy (dmax = 0.93) (Table 1). 
Chemotherapy was given before radiation with cisplatin 1500 mg and 
5FU 1500 mg given every 3 weeks for 3 cycles. Scheduling radiotherapy 
starts on 09-04-2019 until 22-05-2019 according to Picture 8. During 
radiotherapy along with chemotherapy, the patient suffered from acute 
mucositis, dermatitis and moderate degree of xerostomia which could be 
resolved with symptomatic therapy. 
Patients undergo regular follow-up after radiotherapy for the first 6 
months, which is every 4-6 weeks by asking their complaints, undergoing 
clinical and nasopharyngoscopy examinations, complete blood laboratory 
tests, chest radiographs every 3 months to see and control acute side 
effects, especially mucositis and xerostomia, and There was a possibility 
of distant residual in pulmo after 3 months of completion of radiotherapy. 
The acute side effects of the patient were greatly reduced and 6 months 
after radiotherapy the patient was examined for a CT scan, the result was 
a complete response, no longer visible enlargement of cervical lymph 
nodes and clean nasopharynx. (Pictures 7, 8 & 9). 
 
Picture 7. CT Scan After Radiotherapy and Adjuvant Chemotherapy in 
Coronal Section 21-11-2019 
 
 
Picture 8. CT Scan After Radiotherapy and Adjuvant Chemotherapy of 
Sagittal Section 11-21-2019 
 
 
Picture 9. CT Scan after Radiotherapy and Adjuvant Chemotherapy of Axial 
Cross Section 21-11-2019 








It has been reported the case of a 49 year old male patient diagnosed 
with NPC stage IV (T2N3M0) with 3 cycles of radiotherapy and neo-
adjuvant chemotherapy with 66 Gy radiotherapy. 6 months after radiation, 
the patient expressed a complete response with side effects that were well 
tolerated and the patient's main complaint, namely ringing in the ears, was 
no longer felt. 
According to a study by Hui et al, 2009, there were 65 patients with 
stage III-IV randomly assigned to cisplatin / docetaxel for 2 cycles, followed 
by chemo radiotherapy (2/66 Gy + concurrent cisplatin). The results were 
compared with chemo radiatherapy alone. Neo adjuvant chemotherapy 
showed an increase in the 3-year survival rate from 68 to 94%. However, 
the 3-year disease-free survival rate has increased from 60 to 88% and the 
calculation was not statistically significant [14]. 
In the case report: radiotherapy with neoadjuvant chemotherapy on 
nasopharyngeal carcinoma (NPC) advanced stage patients benefited from 
better outcomes such as the study. 
According to the study by Xun et al, 2016, Performed this meta-analysis 
to study the efficacy of neoadjuvant chemotherapy followed by radiation in 
the treatment of advanced nasopharyngeal carcinoma. Then search the 
Medline and Wanfang databases to screen and include prospective 
randomized controlled trials of neoadjuvant chemotherapy plus radiation 
versus radiotherapy in the local treatment of advanced nasopharyngeal 
carcinoma. The pooled 5-year total survival, 5-year disease survival, 
recurrence rate, and metastatic [15]. 
The results were five prospective clinical studies in this meta-analysis. 
The total number of cases included in the study was 1277. Total 5-year 
survival and 5-year disease-free survival did not differ statistically between 
the neoadjuvant chemotherapy plus radiation and radiotherapy groups. May 
reduce the risk of recurrence and metastasis but not maintain overall 5-year 
survival and 5-year disease-free survival compared with radiotherapy alone 
in patients with advanced nasopharyngeal carcinoma [15]. 
In the case report: radiotherapy with neoadjuvant chemotherapy on 
nasopharyngeal carcinoma (NPC) advanced stage, neoajuvan chemotherapy 
followed by radiotherapy was carried out and obtained a complete response 
with tolerable side effects. this case was monitored for one year from 2018 
to 2019 [15].  
3. CONCLUSION 
The results of the safeguarding of the case report: radiotherapy with 
neoadjuvant chemotherapy on nasopharyngeal carcinoma (NPC) advanced 
stage, it can be concluded that concurrent radiotherapy that was previously 
performed by neo-adjuvant chemotherapy produces a complete response 
with side effects that can be tolerated well and the main complaint of the 
patient is that the ear is buzzing no longer felt. It is hoped that further studies 
with more samples and the same therapeutic treatment are expected 
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dose Actual Validate 
(cc) (cGy) (cGy) (cGy) (%) (cc) (cGy) 
Spinal cord 1 (*1081) 12.04 42 4077 2221.8 max dose   4500 4077cGy 100 
PTV 1 (*1081) 582.05 1667 4299 4536 
mean DVH 
volume 95 553.52 3800 95%/553.52cc 100 
GTV 1 (*1081) 134.54 3681 4300 4084 
mean DVH 
volume 95 127.81 3800 99.46%/133.81cc  100 
Bulbus occuli 
dx 1 (*1081) 10.21 2 80 39 max dose   5000 80cGy 100 
Bulbus occuli 
sin 1 (*1081) 10.64 3 93 45 max dose   5000 93cGy 100 
Lens Opt dx 1 (*1081) 0.25 14 45 30 max dose   1000 45cGy 100 
Lens Opt Sin 1 (*1081) 0.21 13 46 31 max dose   1000 46cGy 100 
N Opt dx 1 (*1081) 0.65 41 95 59 max dose   5400 95cGy 100 
N Opt sin 1 (*1081) 0.66 44 100 63 max dose   5400 100cGy 100 
Chyasm Opt 1 (*1081) 2.07 92 146 124 max dose   5400 146cGy 100 
CTV 1 (*1081) 245.21 3387 4277 4072 
mean DVH 
volume 95 232.95 3800 98.48%/243.46cc 100 
Esofagus 1 (*1081) 6.91 148 4070 932 OAR mean     3400 932cGy 100 
Brain steam 1 (*1081) 22.9 107 3984 2269 max dose     3400 3984cGy 100 
PTV SCl 1 (*1081) 90.64 2398 4359 4267 
mean DVH 
volume 95 86.19 3800 96.38%/87.36cc 100 
CTV SCl 1 (*1081) 11.82 3619 4325 4286 
mean DVH 
volume 95 11.23 3800 99.96%/11.82cc 100 
 
 
 
